Goelzer Investment Management Inc. Buys 198 Shares of Stryker Corporation (NYSE:SYK)

Goelzer Investment Management Inc. increased its position in Stryker Corporation (NYSE:SYK) by 19.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,213 shares of the medical technology company’s stock after acquiring an additional 198 shares during the quarter. Goelzer Investment Management Inc.’s holdings in Stryker were worth $452,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of SYK. Capital A Wealth Management LLC bought a new position in shares of Stryker in the fourth quarter worth $26,000. Rakuten Securities Inc. increased its stake in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 68 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in Stryker during the first quarter valued at about $32,000. City Holding Co. lifted its stake in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 74 shares during the last quarter. Finally, VSM Wealth Advisory LLC bought a new position in shares of Stryker during the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.0%

NYSE SYK opened at $392.00 on Friday. The stock has a market cap of $149.62 billion, a P/E ratio of 52.97, a price-to-earnings-growth ratio of 2.95 and a beta of 0.91. Stryker Corporation has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock has a 50 day simple moving average of $382.39 and a two-hundred day simple moving average of $375.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.50 earnings per share. On average, analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker’s dividend payout ratio is 45.41%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Sanford C. Bernstein set a $450.00 target price on Stryker in a research note on Monday, May 5th. Evercore ISI lowered their price objective on shares of Stryker from $400.00 to $390.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Truist Financial increased their target price on shares of Stryker from $390.00 to $400.00 and gave the company a “hold” rating in a report on Monday, May 5th. Citigroup reiterated a “buy” rating and issued a $455.00 target price (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $427.30.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the transaction, the director directly owned 3,417,326 shares of the company’s stock, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.